Proteon Therapeutics Inc (NDAQ:PRTO) was downgraded by HC Wainwright from a “buy” rating to a “neutral” rating in a research report issued on Friday. They currently have a $3.00 price target on the stock.
Shares of Proteon Therapeutics (NDAQ:PRTO) opened at 1.65 on Friday. The firm has a 50 day moving average price of $1.87 and a 200-day moving average price of $5.83. Proteon Therapeutics has a 12-month low of $1.40 and a 12-month high of $11.63. The company’s market cap is $27.38 million.
Proteon Therapeutics Company Profile
Proteon Therapeutics, Inc is a late-stage biopharmaceutical company, which focuses on the development of pharmaceuticals to address the needs of patients with renal and vascular disease. The Company is involved in research and development activities. The Company’s product candidate, product candidate, vonapanitase, formerly PRT-201, is a recombinant human elastase that it is developing to manage vascular access failure in patients with chronic kidney disease undergoing or planning for hemodialysis, a lifesaving treatment that cannot be conducted without a functioning vascular access.